$30m milestone for Threshold as Merck Serono begins second Phase III trial with TH-302
This article was originally published in Scrip
Executive Summary
Concurrent with Merck Serono's initiation of the Phase III MAESTRO clinical trial in pancreatic cancer, Threshold Pharmaceuticals earned a $30 million milestone payment from Merck KGaA under the terms of their nearly year-old partnership for the South San Francisco-based company's tumor hypoxia-targeting small molecule TH-302.